Nesuparib is under clinical development by Onconic Therapeutics and currently in Phase I for Pancreatic Ductal Adenocarcinoma. According to GlobalData, Phase I drugs for Pancreatic Ductal Adenocarcinoma does not have sufficient historical data to build an indication benchmark PTSR for Phase I. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the Nesuparib LoA Report. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Nesuparib overview
JPI-547 (NOV-1402) is under development for the treatment of fallopian tube cancer, primary peritoneal cancer and non-small cell lung cancer. The drug candidate is administered orally. It acts by targeting poly (ADP-ribose) polymerase 1,2 and 3 (PARP) 1and tankyrase (TNKS). It is a new molecular entity (NME).
It was also under development for solid tumors including colorectal cancer, advanced or metastatic pancreatic ductal adenocarcinoma (PDAC), high grade serous ovarian cancer, triple negative breast cancer, castration-resistant prostate cancer, gastric cancer and endometrial cancer.
Onconic Therapeutics overview
Onconic Therapeutics., is a provider of drug development services. The company is headquartered Republic of Korea (South Korea).
For a complete picture of Nesuparib’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
